Biochip-based detection of KRAS mutation in non-small cell lung cancer.

Gernot Kriegshäuser, Gerhild Fabjani, Barbara Ziegler, Sabine Zöchbauer-Müller, Adelheid End, Robert Zeillinger

Open access · goldAbstract readEvaluation Study

In one paragraph

Article in International journal of molecular sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.5field-weighted citation impact, top 30% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

Non-small cell lung cancer: the era of targeted therapy.Lung Cancer (Auckland, N.Z.) · 2012
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Gernot KriegshäuserViennaLab Diagnostics GmbH, 1120 Vienna, Austria. kriegshauser@viennalab.co.at

Gerhild Fabjani

Barbara Ziegler

Sabine Zöchbauer-Müller

Adelheid End

Robert Zeillinger

Ludwig Boltzmann Gesellschaft · ATMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study is aimed at evaluating the potential of a biochip assay to sensitively detect KRAS mutation in DNA from non-small cell lung cancer (NSCLC) tissue samples. The assay covers 10 mutations in codons 12 and 13 of the KRAS gene, and is based on mutant-enriched PCR followed by reverse-hybridization of biotinylated amplification products to an array of sequence-specific probes immobilized on the tip of a rectangular plastic stick (biochip). Biochip hybridization identified 17 (21%) samples to carry a KRAS mutation of which 16 (33%) were adenocarcinomas and 1 (3%) was a squamous cell carcinoma. All mutations were confirmed by DNA sequencing. Using 10 ng of starting DNA, the biochip assay demonstrated a detection limit of 1% mutant sequence in a background of wild-type DNA. Our results suggest that the biochip assay is a sensitive alternative to protocols currently in use for KRAS mutation testing on limited quantity samples.

Indexed as

MutationOligonucleotide Array Sequence AnalysisAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Non-Small-Cell LungCase-Control StudiesFemaleHumansLung NeoplasmsMaleMiddle AgedProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)ras ProteinsBiomarkers, TumorKRAS protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)ras Proteinsbiochip hybridizationKRASmutation detectionnon-small cell lung cancer

Identifiers

PMID22272089

DOI10.3390/ijms12128530

PMCPMC3257086

OpenAlexW1972980271

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.